Table 1.
Demographic data and clinical parameters from patients with Hashimoto thyroiditis (HT).
| Patients | Gender/Age | Ethnicity | TSH (μUI/ml) | FT4 (ng/dl) | TPO Ab (UI/ml) | Tg Ab (UI/ml) | Disease duration (years) | Current treatment |
|---|---|---|---|---|---|---|---|---|
| HT01 | F/28 | Caucasian | ND | ND | ND | ND | 08 y | LT4 |
| HT02 | F/57 | Caucasian | 1.61 | 0.84 | 51.27 | ND | 01 y | NR |
| HT03 | F/35 | Caucasian | ND | ND | ND | ND | 01 y | NR |
| HT04 | F/28 | Afrodescendent | ND | ND | ND | ND | 05 y | NR |
| HT05 | F/55 | Caucasian | ND | ND | ND | ND | 03 y | LT4 |
| HT06 | F/29 | Caucasian | 0.01 | 2.6 | 356 | ND | 13 y | NR |
| HT07 | F/56 | Caucasian | 5.17 | 1.23 | ND | ND | 25 y | LT4 |
| HT08 | F/26 | Caucasian | 6.55 | 1.2 | >600 | 241.3 | 04 y | LT4 |
| HT09 | F/42 | Caucasian | 9.86 | ND | 71 | ND | 12 y | LT4 |
| HT10 | F/67 | Caucasian | 12.21 | 1.1 | 463 | ND | 05 y | LT4 |
| HT11 | F/40 | Caucasian | 17 | 0.92 | 325 | ND | 03 y | LT4 |
| HT12 | M/58 | Caucasian | 7.58 | 1.2 | ND | ND | 05 y | LT4 |
| HT13 | F/50 | Afrodescendent | 51 | 0.3 | 109 | 111 | 02 y | LT4 |
| HT14 | F/53 | Afrodescendent | 14 | 0.87 | 1,683 | 6,652 | 42 y | LT4 |
| HT15 | F/54 | Caucasian | 3.41 | 1.21 | ND | ND | 25 y | NR |
| HT16 | F/64 | Caucasian | 1.53 | 1.84 | >2,000 | ND | 25 y | LT4 |
| HT17 | F/52 | Caucasian | 9.85 | 0.57 | 250 | 11.58 | 05 y | LT4 |
| HT18 | F/45 | Caucasian | 5.51 | 0.62 | 160 | 137.8 | 02 y | LT4 |
| HT19 | F/63 | Afrodescendent | ND | ND | ND | ND | 17 y | LT4 |
| HT20 | F/53 | Caucasian | ND | ND | ND | ND | 10 y | LT4 |
| HT21 | F/82 | Afrodescendent | ND | ND | ND | ND | 10 y | NR |
| HT22 | F/54 | Caucasian | ND | ND | 211.8 | 56.53 | 20 y | LT4 |
| HT23 | F/38 | Afrodescendent | ND | ND | ND | ND | 14 y | LT4 |
| HT24 | F/65 | Caucasian | 4.52 | ND | ND | ND | 10 y | LT4 |
| HT25 | F/52 | Afrodescendent | 10.1 | ND | ND | ND | 06 y | LT4 |
| HT26 | F/65 | Afrodescendent | 4.72 | ND | ND | ND | 05 y | LT4 |
| HT27 | M/62 | Caucasian | 16.8 | 2.05 | 10.82 | 42.81 | 03 y | LT4 |
| HT28 | F/47 | Caucasian | 1.26 | 1.1 | ND | ND | 21 y | LT4 |
| HT29 | F/35 | Caucasian | 9.48 | ND | ND | ND | 07 y | LT4 |
| HT30 | F/51 | Afrodescendent | 3.2 | 0.89 | 270 | 143.23 | 18 y | NR |
| HT31 | F/45 | Caucasian | 4.33 | 1.06 | 159 | 214 | 04 y | LT4 |
| HT32 | M/66 | Caucasian | ND | ND | ND | ND | 03 y | NR |
| HT33 | M/56 | Caucasian | 0.52 | 1.73 | 970 | 26 | 0.9 y | LT4 |
| HT34 | F/23 | Caucasian | 2.03 | 0.96 | 1,840 | 8.58 | 05 y | LT4 |
| HT35 | F/44 | Caucasian | 0.97 | ND | ND | ND | 07 y | LT4 |
| HT36 | F/45 | Caucasian | ND | ND | ND | ND | ND | LT4 |
| HT37 | F/49 | Caucasian | 4.91 | 0.95 | 0.52 | 57 | 07 y | LT4 |
| HT38 | F/43 | Caucasian | 0.48 | 1.1 | 366 | 5.06 | 02 y | LT4 |
| HT39 | F/52 | Caucasian | 4.89 | 1.24 | 282 | >1,000 | 10 y | LT4 |
| HT40 | F/27 | Caucasian | ND | ND | ND | ND | ND | LT4 |
HT, Hashimoto thyroiditis; F, female; M, male; TSH, thyroid-stimulating hormone (Reference: 0.38–5.33 μUI/ml); FT4, free thyroxine (Reference: 0.54–1.24 ng/dl); TPO Ab, anti-thyroid peroxidase antibodies (Reference: <9 UI/ml); Tg Ab, anti-thyroglobulin antibodies (Reference: <4 UI/ml); y, years; ND, not determined; LT4, oral levothyroxine sodium; NR, non-thyroid hormone replacement.